Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Valve Prosthesis Implantation | 5 | 2022 | 28 | 2.580 |
Why?
|
| Extracorporeal Membrane Oxygenation | 5 | 2022 | 23 | 2.400 |
Why?
|
| Blood Vessel Prosthesis Implantation | 4 | 2022 | 21 | 1.920 |
Why?
|
| Heart Neoplasms | 4 | 2021 | 13 | 1.900 |
Why?
|
| Endocarditis | 3 | 2022 | 10 | 1.790 |
Why?
|
| Postoperative Complications | 7 | 2022 | 934 | 1.150 |
Why?
|
| Endocarditis, Bacterial | 3 | 2022 | 12 | 1.080 |
Why?
|
| Cardiac Surgical Procedures | 7 | 2019 | 45 | 0.850 |
Why?
|
| Marfan Syndrome | 1 | 2023 | 4 | 0.850 |
Why?
|
| Humans | 39 | 2023 | 28573 | 0.850 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2022 | 10 | 0.820 |
Why?
|
| Aneurysm, False | 2 | 2016 | 7 | 0.820 |
Why?
|
| Pulmonary Valve | 1 | 2022 | 12 | 0.790 |
Why?
|
| Heart Ventricles | 4 | 2017 | 115 | 0.790 |
Why?
|
| Aortic Aneurysm, Thoracic | 3 | 2016 | 10 | 0.760 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2012 | 9 | 0.760 |
Why?
|
| Pleural Neoplasms | 1 | 2021 | 11 | 0.750 |
Why?
|
| Thymus Neoplasms | 1 | 2021 | 11 | 0.750 |
Why?
|
| Mesothelioma | 1 | 2021 | 14 | 0.750 |
Why?
|
| Stents | 2 | 2016 | 86 | 0.750 |
Why?
|
| Female | 25 | 2023 | 15823 | 0.720 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2020 | 11 | 0.720 |
Why?
|
| Treatment Outcome | 11 | 2022 | 3621 | 0.720 |
Why?
|
| Hospital Mortality | 4 | 2020 | 148 | 0.710 |
Why?
|
| Heart Aneurysm | 2 | 2013 | 8 | 0.700 |
Why?
|
| Male | 24 | 2022 | 15403 | 0.700 |
Why?
|
| Lung Diseases | 1 | 2020 | 46 | 0.700 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 35 | 0.690 |
Why?
|
| Reoperation | 4 | 2022 | 917 | 0.690 |
Why?
|
| Aortic Valve | 5 | 2020 | 26 | 0.680 |
Why?
|
| Heart Atria | 2 | 2016 | 30 | 0.660 |
Why?
|
| Vascular Surgical Procedures | 3 | 2021 | 26 | 0.650 |
Why?
|
| Coronary Artery Bypass | 4 | 2015 | 30 | 0.640 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 8 | 0.630 |
Why?
|
| Aortic Aneurysm | 2 | 2016 | 14 | 0.630 |
Why?
|
| Stroke | 1 | 2022 | 276 | 0.610 |
Why?
|
| Radiography, Thoracic | 2 | 2015 | 28 | 0.590 |
Why?
|
| Sternotomy | 2 | 2015 | 2 | 0.590 |
Why?
|
| Retrospective Studies | 11 | 2022 | 3614 | 0.570 |
Why?
|
| Bioprosthesis | 2 | 2017 | 7 | 0.570 |
Why?
|
| Sarcoma | 1 | 2020 | 144 | 0.560 |
Why?
|
| Middle Aged | 19 | 2021 | 9324 | 0.560 |
Why?
|
| United States | 7 | 2023 | 2201 | 0.550 |
Why?
|
| Endarterectomy | 1 | 2016 | 1 | 0.550 |
Why?
|
| Femoral Artery | 1 | 2016 | 5 | 0.540 |
Why?
|
| Intermittent Claudication | 1 | 2016 | 3 | 0.540 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 5 | 0.540 |
Why?
|
| Adult | 12 | 2023 | 8175 | 0.530 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 51 | 0.530 |
Why?
|
| Aged | 17 | 2021 | 9344 | 0.530 |
Why?
|
| Thoracotomy | 3 | 2015 | 29 | 0.530 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2016 | 12 | 0.530 |
Why?
|
| Cause of Death | 1 | 2016 | 64 | 0.520 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 552 | 0.520 |
Why?
|
| Endovascular Procedures | 1 | 2016 | 34 | 0.510 |
Why?
|
| Pneumopericardium | 1 | 2015 | 1 | 0.490 |
Why?
|
| Intestinal Mucosa | 1 | 2016 | 192 | 0.480 |
Why?
|
| Cardiopulmonary Bypass | 5 | 2016 | 21 | 0.470 |
Why?
|
| Heart Failure | 2 | 2017 | 179 | 0.460 |
Why?
|
| Mandibulofacial Dysostosis | 1 | 2013 | 1 | 0.440 |
Why?
|
| Sinus of Valsalva | 1 | 2013 | 4 | 0.430 |
Why?
|
| Aortic Valve Stenosis | 1 | 2013 | 23 | 0.420 |
Why?
|
| Calcinosis | 1 | 2013 | 49 | 0.420 |
Why?
|
| Coronary Artery Disease | 2 | 2012 | 141 | 0.400 |
Why?
|
| Heart-Assist Devices | 1 | 2012 | 18 | 0.390 |
Why?
|
| Thoracic Arteries | 1 | 2011 | 2 | 0.380 |
Why?
|
| Hematoma | 1 | 2011 | 19 | 0.370 |
Why?
|
| Fibroma | 1 | 2011 | 5 | 0.370 |
Why?
|
| Cocaine-Related Disorders | 1 | 2011 | 13 | 0.360 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2016 | 772 | 0.360 |
Why?
|
| Hospitalization | 2 | 2023 | 323 | 0.340 |
Why?
|
| Hemorrhage | 2 | 2020 | 82 | 0.330 |
Why?
|
| Prosthesis Failure | 1 | 2013 | 539 | 0.330 |
Why?
|
| Risk Assessment | 3 | 2019 | 676 | 0.320 |
Why?
|
| Heart Arrest, Induced | 3 | 2013 | 3 | 0.320 |
Why?
|
| Myocardial Infarction | 2 | 2007 | 147 | 0.310 |
Why?
|
| Pericarditis | 1 | 2007 | 1 | 0.280 |
Why?
|
| Risk Factors | 4 | 2022 | 2414 | 0.240 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 4901 | 0.220 |
Why?
|
| Arterioles | 3 | 2012 | 12 | 0.220 |
Why?
|
| Biopsy | 2 | 2016 | 220 | 0.210 |
Why?
|
| Postpartum Period | 1 | 2023 | 24 | 0.210 |
Why?
|
| Catheterization | 1 | 2022 | 45 | 0.200 |
Why?
|
| Lower Extremity | 1 | 2022 | 40 | 0.200 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2016 | 4 | 0.200 |
Why?
|
| Length of Stay | 2 | 2022 | 330 | 0.200 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2013 | 39 | 0.190 |
Why?
|
| Diabetes Mellitus | 2 | 2013 | 137 | 0.190 |
Why?
|
| Propensity Score | 1 | 2021 | 36 | 0.190 |
Why?
|
| Ischemia | 1 | 2021 | 23 | 0.190 |
Why?
|
| Renal Dialysis | 1 | 2022 | 123 | 0.180 |
Why?
|
| Aorta | 2 | 2021 | 16 | 0.180 |
Why?
|
| SEER Program | 1 | 2020 | 41 | 0.180 |
Why?
|
| Acute Disease | 1 | 2021 | 208 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 11 | 0.170 |
Why?
|
| Incidence | 1 | 2023 | 774 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2013 | 191 | 0.170 |
Why?
|
| Myocardial Ischemia | 1 | 2021 | 43 | 0.170 |
Why?
|
| Adipose Tissue | 1 | 2021 | 79 | 0.170 |
Why?
|
| Myocardium | 2 | 2013 | 105 | 0.170 |
Why?
|
| Time Factors | 4 | 2016 | 1500 | 0.170 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1864 | 0.170 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 373 | 0.170 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 352 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 43 | 0.160 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 372 | 0.160 |
Why?
|
| Young Adult | 3 | 2020 | 2104 | 0.160 |
Why?
|
| Heparin | 1 | 2019 | 22 | 0.160 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 137 | 0.150 |
Why?
|
| Anticoagulants | 1 | 2019 | 90 | 0.150 |
Why?
|
| Infant | 1 | 2020 | 590 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 121 | 0.150 |
Why?
|
| Prognosis | 1 | 2020 | 826 | 0.150 |
Why?
|
| Child, Preschool | 1 | 2020 | 691 | 0.140 |
Why?
|
| Infant, Newborn | 1 | 2020 | 657 | 0.140 |
Why?
|
| Heart Transplantation | 1 | 2017 | 30 | 0.140 |
Why?
|
| Polyethylene Terephthalates | 1 | 2017 | 3 | 0.140 |
Why?
|
| Graft Rejection | 1 | 2017 | 71 | 0.140 |
Why?
|
| Heart Valve Prosthesis | 1 | 2017 | 13 | 0.140 |
Why?
|
| Mitral Valve Stenosis | 1 | 2016 | 1 | 0.140 |
Why?
|
| Adolescent | 2 | 2020 | 2322 | 0.140 |
Why?
|
| Heterografts | 1 | 2016 | 16 | 0.140 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2016 | 15 | 0.140 |
Why?
|
| Swine | 1 | 2016 | 82 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2016 | 267 | 0.130 |
Why?
|
| Time Out, Healthcare | 1 | 2016 | 1 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 180 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2017 | 166 | 0.130 |
Why?
|
| Operating Rooms | 1 | 2016 | 15 | 0.130 |
Why?
|
| Checklist | 1 | 2016 | 40 | 0.120 |
Why?
|
| Tricuspid Valve | 1 | 2015 | 2 | 0.120 |
Why?
|
| Survival Rate | 2 | 2017 | 356 | 0.120 |
Why?
|
| Vena Cava, Inferior | 1 | 2015 | 11 | 0.120 |
Why?
|
| Balloon Occlusion | 1 | 2015 | 9 | 0.120 |
Why?
|
| Child | 1 | 2020 | 1424 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2016 | 359 | 0.120 |
Why?
|
| Foreign Bodies | 1 | 2015 | 30 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2020 | 1942 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 33 | 0.110 |
Why?
|
| Moon | 1 | 2013 | 2 | 0.110 |
Why?
|
| Heart Bypass, Left | 1 | 2013 | 1 | 0.110 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 192 | 0.110 |
Why?
|
| Seasons | 1 | 2013 | 24 | 0.110 |
Why?
|
| Depression | 1 | 2017 | 454 | 0.110 |
Why?
|
| Intraoperative Care | 1 | 2013 | 43 | 0.110 |
Why?
|
| Atrial Appendage | 1 | 2013 | 37 | 0.110 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2016 | 318 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2013 | 41 | 0.100 |
Why?
|
| Vasodilation | 1 | 2012 | 5 | 0.100 |
Why?
|
| Microcirculation | 1 | 2012 | 29 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 990 | 0.100 |
Why?
|
| Apoptosis | 1 | 2013 | 205 | 0.100 |
Why?
|
| Coronary Vessels | 1 | 2012 | 34 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 40 | 0.100 |
Why?
|
| Risk Adjustment | 1 | 2012 | 11 | 0.100 |
Why?
|
| Muscle, Skeletal | 2 | 2012 | 398 | 0.100 |
Why?
|
| Rupture, Spontaneous | 1 | 2011 | 5 | 0.100 |
Why?
|
| Intercostal Muscles | 1 | 2011 | 3 | 0.100 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 31 | 0.100 |
Why?
|
| Thromboxane A2 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Vasoconstrictor Agents | 1 | 2011 | 28 | 0.090 |
Why?
|
| Radiography | 1 | 2013 | 651 | 0.090 |
Why?
|
| Muscle Contraction | 1 | 2011 | 68 | 0.090 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2011 | 10 | 0.090 |
Why?
|
| Echocardiography | 1 | 2011 | 114 | 0.090 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2011 | 81 | 0.080 |
Why?
|
| Animals | 1 | 2016 | 3814 | 0.080 |
Why?
|
| Fibrosis | 1 | 2007 | 30 | 0.070 |
Why?
|
| Syndrome | 1 | 2007 | 82 | 0.070 |
Why?
|
| Coronary Angiography | 1 | 2007 | 84 | 0.070 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2006 | 11 | 0.060 |
Why?
|
| Inflammation | 2 | 2021 | 288 | 0.060 |
Why?
|
| Disease Progression | 1 | 2006 | 722 | 0.050 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2013 | 2 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2012 | 49 | 0.050 |
Why?
|
| Chemokine CCL2 | 1 | 2021 | 19 | 0.050 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 56 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2021 | 79 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 68 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2021 | 33 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 26 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 137 | 0.040 |
Why?
|
| Atherosclerosis | 1 | 2021 | 56 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 178 | 0.040 |
Why?
|
| Veins | 1 | 2019 | 9 | 0.040 |
Why?
|
| Arteries | 1 | 2019 | 16 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2020 | 162 | 0.040 |
Why?
|
| Obesity | 1 | 2021 | 322 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 58 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2017 | 81 | 0.030 |
Why?
|
| Psychometrics | 1 | 2017 | 246 | 0.030 |
Why?
|
| Systems Theory | 1 | 2016 | 3 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 26 | 0.030 |
Why?
|
| Medication Errors | 1 | 2016 | 15 | 0.030 |
Why?
|
| Medical Errors | 1 | 2016 | 28 | 0.030 |
Why?
|
| Nursing Staff, Hospital | 1 | 2016 | 48 | 0.030 |
Why?
|
| Patient Safety | 1 | 2016 | 55 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 503 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2016 | 161 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2016 | 141 | 0.030 |
Why?
|
| Cardioplegic Solutions | 1 | 2013 | 1 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2013 | 12 | 0.030 |
Why?
|
| Rhode Island | 1 | 2013 | 2 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 36 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 28 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 121 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 2012 | 5 | 0.030 |
Why?
|
| Nitroprusside | 1 | 2012 | 6 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2012 | 19 | 0.030 |
Why?
|
| Vasoconstriction | 1 | 2012 | 16 | 0.030 |
Why?
|
| Substance P | 1 | 2012 | 12 | 0.030 |
Why?
|
| Tyrosine | 1 | 2012 | 25 | 0.030 |
Why?
|
| Protein Kinase C-alpha | 1 | 2012 | 8 | 0.030 |
Why?
|
| Protein Kinase C beta | 1 | 2012 | 8 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2012 | 34 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 255 | 0.030 |
Why?
|
| Chicago | 1 | 2016 | 942 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 39 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2012 | 30 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2013 | 269 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2012 | 149 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2012 | 52 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 75 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 333 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 398 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 50 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 438 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 477 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 204 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 282 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 599 | 0.020 |
Why?
|
| Biomarkers | 1 | 2012 | 601 | 0.020 |
Why?
|